CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 190 enrolled
Drug / intervention
Vitamin D control dose +1 moredrug
Likely dose
Vitamin D control dose 18,000 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01523496
NCT01523496Phase 3Completed

Vitamin D Supplementation and HIV-related Complications in Children and Young Adults

University Hospitals Cleveland Medical Center·interventional·Posted Feb 1, 2012·Updated Mar 8, 2018

In Brief

A Phase 3 clinical trial evaluating Vitamin D control dose and Vitamin D supplementation- for HIV Infections. Completed, enrolled 190 participants across 2 sites.

Detailed Summary

The purpose of this study is to determine the correct dose of Vitamin D to give to prevent HIV related complications.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
CollaboratorsEmory University

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 1, 2012
Enrollment StartDec 1, 2011
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 14.4 years ago

Interventions

Vitamin D control dosedrug

18,000 IU per month

Vitamin D supplementation-drug

60,000 IU per month(medium dose) or 120,000 IU/month(high dose)